Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

. Additional clinical programs include the development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as Type 2 diabetes, multiple sclerosis and vascular restenosis, and CCX354, a CCR1 antagonist in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implement
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Mass. , July 28, 2015  Today, Sekisui ... A compact, affordable and efficient instrument, with a broad ... bring significant benefits to the physicians, office or hospital ... of up to 580 tests/hour with ISE, 72 patient ... and has 36 onboard assays (+3 ISE) to meet ...
(Date:7/28/2015)... ROCHESTER, N.Y. , July 28, 2015 ... of clinical trial imaging solutions, today announced that it ... the 4:00 p.m. ET market close on Tuesday, August ... chief executive officer, and Jim Groff , chief ... to discuss the company,s financial results and provide a ...
(Date:7/28/2015)... -- Zipnosis, the first virtual care solution to empower health care ... branded virtual care service line, announced an agreement with ... currently in use. ... As health systems consider how ... of providing their own branded online care for common medical ...
Breaking Medicine Technology:Sekisui Diagnostics Announces Launch of SK500 Clinical Chemistry System for US Laboratories 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 3Zipnosis Announces Group Health to use Virtual Care Service Line 2Zipnosis Announces Group Health to use Virtual Care Service Line 3
... Express Scripts, Inc. (Nasdaq: ESRX ) announced ... operations of $290.4 million and $1,275.8 million, or $0.59 and ... detailed in Table 4 were $0.82 and $2.97 per diluted ... "Through our unwavering focus on innovation, service and ...
... 2012  Endo Pharmaceuticals Holdings (Nasdaq: ENDP ) today ... corporate overview at the Cowen & Co. 32nd Annual Heath ... ET.  The conference will be held at the Boston Marriott ... and audio archive of the presentation will be available on ...
Cached Medicine Technology:Express Scripts Reports Fourth Quarter Results 2Express Scripts Reports Fourth Quarter Results 3Express Scripts Reports Fourth Quarter Results 4Express Scripts Reports Fourth Quarter Results 5Express Scripts Reports Fourth Quarter Results 6Express Scripts Reports Fourth Quarter Results 7Express Scripts Reports Fourth Quarter Results 8Express Scripts Reports Fourth Quarter Results 9Express Scripts Reports Fourth Quarter Results 10Express Scripts Reports Fourth Quarter Results 11Express Scripts Reports Fourth Quarter Results 12
(Date:7/28/2015)... Calif (PRWEB) , ... July 28, 2015 , ... ... the United States with 1 in 68 children currently affected with the disorder. ... their child on the road to recovery is extremely daunting. That’s where Talk ...
(Date:7/28/2015)... Jose, CA (PRWEB) , ... July 28, 2015 ... ... services, intelligent gateways, and embedded building blocks for edge devices that enable the ... equipped with 4th generation Intel® Core™ i7/i5 processor to provide exceptional computing power ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... U.S. commercial launch of its ORTHALIGN PLUS® system, a palm-sized, single-use navigation device ... , “OrthAlign successfully combined precision with practicality in a revolutionary way for Total ...
(Date:7/28/2015)... , ... July 28, 2015 , ... On July 16th ... refused to schedule the hearing of proposed bills and laws revolving the implementation of ... infections to date. Some vigilante ministers are continuing to hand out clean needles to ...
(Date:7/28/2015)... ... July 28, 2015 , ... BiologicsMD, Inc. , ... for the treatment of bone disorders and conditions of hair loss, announced that ... Proteins of Collagen Binding-Domain and Parathyroid Hormone". The issued patent claims methods of ...
Breaking Medicine News(10 mins):Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 2Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2
... ALBANY, N.Y., June 24 AARP will host a,series ... New York,State this summer and fall to address growing ... be convened through live meetings and,teleconferences to inform AARP ... in New York State and the influence,pharmaceutical companies have ...
... of how to play safely in,the summer sun, ... and a host of outdoor activities to enjoy,everyday, the ... more,time under the sun. With the official start of ... overexposure to the,sun, which can lead to heat-related illness., ...
... status, access and language barriers affect who goes for ... News) -- The higher death rate from colorectal cancer ... socioeconomic, health care access, language and cultural barriers that ... new report finds. , The report, published ...
... researcher Karl Herrup and colleagues at Case Western Reserve ... division in brain cells effectively "puts the brakes" on ... the brakes fail, dementia results. , This discovery could ... disease, which affects up to half the population over ...
... 24, 2008 Rejuvenating newly identified fat compartments in the ... face as it ages, according to new research by plastic ... dyes to identify and map four cheek-fat compartments hidden deep ... tissue fillers or artificial implants, the result is a more ...
... - Awards Target Researchers in Developing Countries ... grant proposals for its Innovative,Libraries in Developing Countries ... programs sponsored by Elsevier, a leading global,publisher of ... due by September 15, 2008. The grants will ...
Cached Medicine News:Health News:AARP to Host Town Hall Meetings on Prescription Drug Marketing Reform 2Health News:Physicians at Northwestern Memorial Offer Sun Safety Tips Just in Time for the Start of Summer 2Health News:Physicians at Northwestern Memorial Offer Sun Safety Tips Just in Time for the Start of Summer 3Health News:Physicians at Northwestern Memorial Offer Sun Safety Tips Just in Time for the Start of Summer 4Health News:Social, Health Care Factors Drive Colon Screen Disparities 2Health News:Alzheimer's disease as a case of brake failure? 2Health News:UT Southwestern: Hidden facial cheek fat compartments are key to youthful appearance 2Health News:Elsevier Foundation Seeks Grant Proposals for Innovative Libraries and New Scholars 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: